Pharmacology Research Today is a free monthly online journal that collates and summarizes the latest research about Pharmacology, including details on pharmacogenomics, drug development, new medications.

Volume 5 (2009), Issue 6 (June)

1. Biophysical and structural studies on the capsid protein of the human immunodeficiency virus type 1: a new drug target?
   ScientificWorldJournal, 9: 404-19. [Abstract] [Full-text]
2. Development of pharmacotherapies for drug addiction: a Rosetta stone approach.
   Nat Rev Drug Discov, 8(6): 500-15. [Abstract] [Full-text]
3. Structures of glycinamide ribonucleotide transformylase (PurN) from Mycobacterium tuberculosis reveal a novel dimer with relevance to drug discovery.
   J Mol Biol, 389(4): 722-33. [Abstract] [Full-text]
4. Fluorinated carbohydrates as lectin ligands: versatile sensors in 19F-detected saturation transfer difference NMR spectroscopy.
   Chemistry, 15(23): 5666-8. [Abstract] [Full-text]
5. The chemist as astronaut: searching for biologically useful space in the chemical universe.
   Biochem Pharmacol, 78(3): 217-23. [Abstract] [Full-text]
6. Analytical control of genotoxic impurities in the pazopanib hydrochloride manufacturing process.
   J Pharm Biomed Anal, 50(2): 144-50. [Abstract] [Full-text]
7. Speciation of Sb(III) and Sb(V) in meglumine antimoniate pharmaceutical formulations by PSA using carbon nanotube electrode.
   J Pharm Biomed Anal, 50(2): 151-7. [Abstract] [Full-text]
8. Pharmacogenetic analyses of a phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil and leucovorin plus either oxaliplatin or cisplatin: a study of the arbeitsgemeinschaft internistische onkologie.
   J Clin Oncol, 27(17): 2863-73. [Abstract] [Full-text]
9. Improved, selective, human intestinal carboxylesterase inhibitors designed to modulate 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (Irinotecan; CPT-11) toxicity.
   J Med Chem, 52(12): 3742-52. [Abstract] [Full-text]
10. Sesterterpenes as tubulin tyrosine ligase inhibitors. First insight of structure-activity relationships and discovery of new lead.
    J Med Chem, 52(12): 3814-28. [Abstract] [Full-text]
11. Toward the back-up of boceprevir (SCH 503034): discovery of new extended P4-capped ketoamide inhibitors of hepatitis C virus NS3 serine protease with improved potency and pharmacokinetic profiles.
    J Med Chem, 52(12): 3679-88. [Abstract] [Full-text]
12. Design, synthesis, and evaluation of N-acyl modified sialic acids as inhibitors of adenoviruses causing epidemic keratoconjunctivitis.
    J Med Chem, 52(12): 3666-78. [Abstract] [Full-text]
13. Design and implementation of an ribonucleic acid (RNA) directed fragment library.
    J Med Chem, 52(12): 3753-61. [Abstract] [Full-text]
14. Rational design, synthesis, and pharmacological properties of new 1,8-naphthyridin-2(1H)-on-3-carboxamide derivatives as highly selective cannabinoid-2 receptor agonists.
    J Med Chem, 52(12): 3644-51. [Abstract] [Full-text]
15. Design and preparation of potent, nonpeptidic, bioavailable renin inhibitors.
    J Med Chem, 52(12): 3689-702. [Abstract] [Full-text]
16. Addressing the challenges of the clinical application of pharmacogenetic testing.
    Clin Pharmacol Ther, 86(1): 28-31. [Abstract] [Full-text]
17. Biomarkers in clinical drug development.
    Clin Pharmacol Ther, 86(1): 26-7. [Abstract] [Full-text]
18. Genetic ancestry modifies pharmacogenetic gene-gene interaction for asthma.
    Pharmacogenet Genomics, 19(7): 489-96. [Abstract] [Full-text]
19. QT as a safety biomarker in drug development.
    Clin Pharmacol Ther, 86(1): 101-4. [Abstract] [Full-text]
20. The value, qualification, and regulatory use of surrogate end points in drug development.
    Clin Pharmacol Ther, 86(1): 32-43. [Abstract] [Full-text]
21. The clinical utility index as a practical multiattribute approach to drug development decisions.
    Clin Pharmacol Ther, 86(1): 105-8. [Abstract] [Full-text]
22. Clinically available pharmacogenomics tests.
    Clin Pharmacol Ther, 86(1): 109-13. [Abstract] [Full-text]
23. Homogeneous recombinant Mycobacterium tuberculosis shikimate dehydrogenase production: an essential step towards target-based drug design.
    Int J Biol Macromol, 45(2): 200-5. [Abstract] [Full-text]
24. Lambda-dynamics free energy simulation methods.
    J Comput Chem, 30(11): 1692-700. [Abstract] [Full-text]
25. Pharmacogenomic variability and anaesthesia.
    Br J Anaesth, 103(1): 14-25. [Abstract] [Full-text]
26. What are next generation innovative therapeutic targets? Clues from genetic, structural, physicochemical, and systems profiles of successful targets.
    J Pharmacol Exp Ther, 330(1): 304-15. [Abstract] [Full-text]
27. Design and synthesis of inhibitors of Hedgehog signaling based on the alkaloid cyclopamine.
    Org Lett, 11(13): 2824-7. [Abstract] [Full-text]
28. The endocannabinoid system: its general strategy of action, tools for its pharmacological manipulation and potential therapeutic exploitation.
    Pharmacol Res, 60(2): 77-84. [Abstract] [Full-text]
29. Psychopharmacology for children: from off label use to registration.
    Eur Neuropsychopharmacol, 19(8): 603-8. [Abstract] [Full-text]

© 2005-2013 Pharmacology Research Today. All Rights Reserved.